Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

$1.90
+0.14 (+7.94%)
(As of 10/4/2024 ET)

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$1.80
$2.02
50-Day Range
$1.45
$1.90
52-Week Range
$1.20
$5.50
Volume
45,255 shs
Average Volume
36,781 shs
Market Capitalization
$20.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 733rd out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    CytoMed Therapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.59% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.59% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
    Receive GDTC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    GDTC Stock News Headlines

    CytoMed Therapeutics Limited (GDTC)
    Notice: Major payout due November 19th - are you on the list?
    On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...
    CytoMed Therapeutics Ltd GDTC
    See More Headlines

    GDTC Stock Analysis - Frequently Asked Questions

    CytoMed Therapeutics' stock was trading at $4.90 on January 1st, 2024. Since then, GDTC stock has decreased by 61.1% and is now trading at $1.9038.
    View the best growth stocks for 2024 here
    .

    CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering on Friday, April 14th 2023. The company issued 2,412,369 shares at $4.00 per share.

    Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Company Calendar

    Today
    10/04/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:GDTC
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $5.00
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $5.00
    Potential Upside/Downside
    +162.6%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Book Value
    $0.78 per share

    Miscellaneous

    Free Float
    N/A
    Market Cap
    $20.83 million
    Optionable
    Not Optionable
    Beta
    0.63
    These 7 Stocks Will Be Magnificent in 2024 Cover

    With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

    Get This Free Report

    This page (NASDAQ:GDTC) was last updated on 10/5/2024 by MarketBeat.com Staff
    From Our Partners